Autolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs Group

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by stock analysts at The Goldman Sachs Group from a "neutral" rating to a "buy" rating in a research note issued on Monday, MarketBeat.com reports. The firm presently has a $7.60 price target on the stock, up from their previous price target of $7.00. The Goldman Sachs Group's price objective suggests a potential upside of 154.18% from the stock's previous close.

Several other research firms have also recently weighed in on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a research note on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $10.15.

Autolus Therapeutics Price Performance

NASDAQ:AUTL traded down $0.09 during mid-day trading on Monday, reaching $2.99. 2,102,730 shares of the company's stock traded hands, compared to its average volume of 1,445,160. Autolus Therapeutics has a 12-month low of $2.92 and a 12-month high of $7.45. The company has a 50 day moving average price of $3.91 and a 200-day moving average price of $3.99. The firm has a market capitalization of $795.62 million, a price-to-earnings ratio of -2.53 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the firm earned ($0.26) earnings per share. As a group, analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several institutional investors have recently added to or reduced their stakes in AUTL. SG Americas Securities LLC bought a new stake in shares of Autolus Therapeutics during the first quarter valued at approximately $127,000. EntryPoint Capital LLC grew its stake in shares of Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock worth $137,000 after acquiring an additional 11,456 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in Autolus Therapeutics by 117.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company's stock worth $21,532,000 after purchasing an additional 1,824,592 shares in the last quarter. Avoro Capital Advisors LLC acquired a new position in Autolus Therapeutics during the 1st quarter valued at approximately $78,765,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company's stock valued at $35,020,000 after buying an additional 2,487,778 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.